Fusion Pharmaceuticals Inc (FUSN) concluded trading on 12/28/23 at a closing price of $9.65, with 2.81 million shares of worth about $27.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 116.85% during that period and on Thursday the price saw a gain of about 6.28%. Currently the company’s common shares owned by public are about 72.41M shares, out of which, 47.75M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fusion Pharmaceuticals Inc (NASDAQ: FUSN) started trading at $9.24, above $0.16 from concluding price of the previous day. However, the stock later moved at a day high price of 10.43, or with a gain of 6.28%. Stock saw a price change of 55.14% in past 5 days and over the past one month there was a price change of 103.59%. Year-to-date (YTD), FUSN shares are showing a performance of 206.35% which increased to 231.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.31 but also hit the highest price of $9.36 during that period. The average intraday trading volume for Fusion Pharmaceuticals Inc shares is 475.08K. The stock is currently trading 64.31% above its 20-day simple moving average (SMA20), while that difference is up 94.90% for SMA50 and it goes to 137.38% higher than SMA200.
Fusion Pharmaceuticals Inc (NASDAQ: FUSN) currently have 72.41M outstanding shares and institutions hold larger chunk of about 47.16% of that.
The stock has a current market capitalization of $698.76M and its 3Y-monthly beta is at -0.88. It has posted earnings per share of -$1.63 in the same period. It has Quick Ratio of 11.63 while making debt-to-equity ratio of 0.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FUSN, volatility over the week remained 12.33% while standing at 10.39% over the month.
Analysts are in expectations that Fusion Pharmaceuticals Inc (FUSN) stock would likely to be making an EPS of $Cedar Fair, L.P. in the current quarter, while forecast for next quarter EPS is $39.57 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $FUSE GROUP HOLDING INC which is $First US Bancshares, Inc. at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $FISION CORP in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 27.81% while it is estimated to increase by 4.10% in next year.
Analysts at 13 brokerage firms have issued recommendations for the Fusion Pharmaceuticals Inc (FUSN)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 13 Wall Street analysts, 13 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on December 27, 2023 offering a Strong buy rating for the stock and assigned a target price range of between $12 and $15 to it.
